Artrya Limited
AYA.AX
Get informed when a big investor buys or sells
+ FollowMarket Cap$490.52M
Close$
$0.30
90.3% downside
Current Fair Value
90.3% downsideOvervalued by 90.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $490.52 Million |
|---|---|
| Enterprise Value | $446.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.17 |
| Beta | 0.59 |
| Outstanding Shares | 162,963,615 |
Return
| Return on Equity | -53.12% |
|---|---|
| Return on Assets | -48.73% |
| Return on Invested Capital | -54.70% |
Valuation & Multiples
| P/E Ratio | -17.3 |
|---|---|
| PEG | -28.33 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 7974.88 |
| Enterprise Value to EBIT | -10.17 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
$300,000
Average shareholder expectationNext Earnings Call
Expected Date
March 2, 2027
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$14,000
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Artrya Limited
43 employees
CEO: John Konstantopoulos Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix...